Panitumumab w leczeniu chorych na uogólnionego raka jelita grubego
Streszczenie
Panitumumab jest ludzkim przeciwciałem monoklonalnym klasy IgG2 zarejestrowanym w terapii chorych na przerzutowego raka jelita grubego. Skuteczność leku potwierdzono podczas stosowania w skojarzeniu z chemioterapią w I linii leczenia zaawansowanego raka jelita grubego oraz w monoterapii po niepowodzeniu schematów zawierających oksaliplatynę, irynotekan oraz fluorouracyl. Warunkiem zastosowania panitumumabu jest wykluczenie obecności mutacji w eksonach 2., 3. i 4. genów KRAS i NRAS oraz mutacji aktywującej (V600E) w genie BRAF. Toksyczność jest typowa dla leków blokujących receptor naskórkowego czynnika wzrostu (EGFR, epidermal growth factor receptor) i nie stanowi czynnika ograniczającego wartość leczenia. Panitumumab ma ugruntowane miejsce w leczeniu chorych na uogólnionego raka jelita grubego z uwagi na znaczący wpływ na poprawę rokowania, korzystny profil bezpieczeństwa oraz dostępność biomarkerów predykcyjnych umożliwiających dobór chorych odnoszących korzyść z leczenia.
Słowa kluczowe: terapia anty-EGFRpanitumumabuogólniony rak jelita grubego
Referencje
- Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2): 338–344.
- Pfeiffer P, Gruenberger T, Glynne-Jones R. Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first? Ther Adv Med Oncol. 2018; 10: 1758835918787993.
- Wysocki P. Recent progress in the systemic treatment of colorectal cancer. Oncol Clin Pract. 2021; 17(4): 157–163.
- Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009; 101(19): 1308–1324.
- Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10): 1626–1634.
- Han CB, Li F, Ma JT, et al. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest. 2012; 30(10): 741–747.
- Chen J, Zeng F, Forrester SJ, et al. Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease. Physiol Rev. 2016; 96(3): 1025–1069.
- Hecht JR, Mitchell E, Neubauer MA, et al. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res. 2010; 16(7): 2205–2213.
- Wojtukiewicz MZ, Sierko E, Szambora P. Patofizjologiczne podstawy terapii ukierunkowanej na zahamowanie funkcji receptora czynnika wzrostu naskórka (EGFR). Oncol Clin Prac. 2010; 6(5): 217–227.
- Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010; 184(1): 512–520.
- Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol. 2010; 17 Suppl 1(Suppl 1): S18–S30.
- Wysocki P, Kwinta Ł, Potocki P, et al. Systemic treatment of patients with solid tumors during the COVID-19 (SARS-CoV-2) pandemic — comprehensive recommendations of the Polish Society of Clinical Oncology. Oncology in Clinical Practice. 2020; 16(2): 41–51.
- Siena S, Cassidy J, Tabernero RL, et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as a first-line treatment in patients with metastatic colorectal cancer: the PRIME trial. Prezentacja na ASCO Gastrointestinal Cancers Symposium; 22-24 stycznia, 2010; Orlando, Floryda, Stany Zjednoczone. Abstrakt 283.
- Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28(31): 4697–4705.
- Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11): 1023–1034.
- Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25(7): 1346–1355.
- Carrato A, Abad A, Massuti B, et al. Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017; 81: 191–202.
- Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014; 32(21): 2240–2247.
- Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017; 28(8): 1713–1729.
- Yoshino T, Watanabe J, Shitara K, et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. J Clin Oncol. 2022; 40(17_suppl): LBA1–LBA1.
- Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017; 317(23): 2392–2401.
- Geredeli C, Yasar N. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. World J Surg Oncol. 2018; 16(1): 67.
- Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14): 1408–1417.
- Dawoud E, Shorbagy DE, Hamza D, et al. Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for first line treatment of metastatic colorectal cancer with wild-type KRAS tumors; a retrospective study. Austral - Asian Journal of Cancer. 2014; 13(1): 5–11.
- Karthaus M, Hofheinz RD, Mineur L, et al. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer. 2016; 115(10): 1215–1222.
- Chen Q, Cheng M, Wang Z, et al. The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore). 2016; 95(50): e5284.
- Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25(1): 107–116.
- Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res. 2015; 21(24): 5469–5479.
- Peeters M, Forget F, Karthaus M, et al. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with wild-type metastatic colorectal carcinoma. ESMO Open. 2018; 3(2): e000297.
- Munemoto Y, Nakamura M, Takahashi M, et al. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Eur J Cancer. 2019; 119: 158–167.
- Modest DP, Karthaus M, Fruehauf S, et al. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). J Clin Oncol. 2022; 40(1): 72–82.
- Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13): 1658–1664.
- Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4): 337–345.
- Yamaguchi T, Iwasa S, Nagashima K, et al. Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer. Anticancer Res. 2016; 36(7): 3531–3536.
- Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014; 15(6): 569–579.
- Taniguchi H, Yamanaka T, Sakai D, et al. Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G. J Clin Oncol. 2018; 36(4_suppl): 745–745.
- Douillard JY, Siena S, Peeters M, et al. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015; 51(10): 1231–1242.
- Douillard J, Siena S, Peeters M, et al. Impact of Baseline Age on Efficacy and Safety of First-Line Panitumumab (Pmab) + Folfox4 Vs Folfox4 Treatment. Ann Oncol. 2014; 25: iv187.
- Asimakopoulou N, Souglakos J, Kentepozidis N, et al. Hellenic Oncology Research Group. Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). J Geriatr Oncol. 2019; 10(1): 143–148.